Table 2.
The association between RNPC1 protein expression and clinicopathologic features in breast cancer
|
Clinicopathologic parameters |
Number of case |
RNPC1 |
RNPC1 |
p
-value |
|---|---|---|---|---|
| Low expression | High expression | |||
|
Age (years) |
|
|
|
|
| ≤55 |
68 |
46 |
22 |
0.631 |
| >55 |
53 |
38 |
15 |
|
|
Tumor Size (cm) |
|
|
|
|
| ≤2 |
38 |
25 |
13 |
0.557 |
| >2 |
83 |
59 |
24 |
|
|
TNM stage |
|
|
|
|
| I |
24 |
15 |
9 |
0.411 |
| II + III |
97 |
69 |
28 |
|
|
Lymph node metastasis |
|
|
|
|
| ≤3 |
96 |
62 |
34 |
0.024 |
| >3 |
25 |
22 |
3 |
|
|
Grade |
|
|
|
|
| I |
7 |
4 |
3 |
0.215 |
| II |
67 |
51 |
16 |
|
| III |
30 |
20 |
10 |
|
|
unclear |
17 |
9 |
8 |
|
|
ER status |
|
|
|
|
|
Negative |
40 |
24 |
16 |
0.181 |
|
Positive |
70 |
53 |
17 |
|
|
unclear |
11 |
7 |
4 |
|
|
PR status |
|
|
|
|
|
Negative |
58 |
46 |
12 |
0.023 |
|
Positive |
63 |
38 |
25 |
|
|
Her2 status |
|
|
|
|
|
Negative |
81 |
61 |
20 |
0.117 |
|
Positive |
32 |
18 |
14 |
|
|
suspect |
8 |
5 |
3 |
|
|
Ki67 |
|
|
|
|
|
≤15% |
43 |
30 |
13 |
0.402 |
|
>15% |
52 |
32 |
20 |
|
|
CK5/6 |
|
|
|
|
|
Negative |
46 |
29 |
17 |
0.800 |
|
Positive |
15 |
10 |
5 |
|
|
P53 |
|
|
|
|
|
Negative |
42 |
32 |
10 |
0.039 |
|
Positive |
52 |
29 |
23 |
|
|
PCNA |
|
|
|
|
|
Negative |
2 |
2 |
0 |
0.619 |
|
+ |
36 |
27 |
9 |
|
|
++ |
22 |
16 |
6 |
|
|
+++ |
12 |
7 |
5 |
|
|
Histology |
|
|
|
|
|
ductal |
106 |
75 |
31 |
0.397 |
| special | 15 | 9 | 6 |
ER: oestrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2.
TNM classification according to the Union Internationale Contre le Cancer criteria. HER2 positivity 3+ in immunohistochemistry or positive fluorescent in situ hybridisation test.